Literature DB >> 1960224

Familial antithrombin III deficiency and Mycoplasma pneumoniae pneumonia.

M D Creagh1, I F Roberts, D J Clark, F E Preston.   

Abstract

A 10 year old girl presented with a massive femoral vein thrombosis associated with Mycoplasma pneumoniae pneumonia. Subsequently type I familial antithrombin III deficiency was diagnosed. It is suggested that prophylactic measures aimed at preventing thrombosis should be considered in acutely ill subjects with infection and familial thrombophilia.

Entities:  

Mesh:

Year:  1991        PMID: 1960224      PMCID: PMC496679          DOI: 10.1136/jcp.44.10.870

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

Review 1.  Actions and interactions of antithrombin and heparin.

Authors:  R D Rosenberg
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

2.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

3.  Hereditary antithrombin III deficiency and thromboembolic disease.

Authors:  D J Filip; J D Eckstein; J J Veltkamp
Journal:  Am J Hematol       Date:  1976       Impact factor: 10.047

Review 4.  Antithrombin III: critical review of assay methods. Significance of variations in health and disease.

Authors:  O R Odegård; U Abildgaard
Journal:  Haemostasis       Date:  1978

5.  [Antithrombin III deficiency and tendency to thrombosis (author's transl)].

Authors:  K Lechner; E Thaler; H Niessner; C Nowotny; H Partsch
Journal:  Wien Klin Wochenschr       Date:  1977-04-01       Impact factor: 1.704

  5 in total
  2 in total

1.  Aortic thrombus and multiple embolisms during a Mycoplasma pneumoniae infection.

Authors:  C Flateau; I Asfalou; A-L Deman; C Ficko; D Andriamanantena; E Fontan; E Viant; L Bonnevie; C Rapp
Journal:  Infection       Date:  2013-05-22       Impact factor: 3.553

Review 2.  Thrombosis associated with mycoplasma pneumoniae infection (Review).

Authors:  Jingwei Liu; Yumei Li
Journal:  Exp Ther Med       Date:  2021-07-07       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.